Indication

HER2-positive Solid Cancers

1 clinical trial

1 product

Clinical trial

A Phase 1 Open-label, Multicenter Dose Escalation and Expansion Study of MT-5111 in Subjects With Previously Treated Advanced HER2-positive Solid Tumors

Status: Terminated, Estimated PCD: 2023-02-01

Product